FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Henk Lokhorst

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Anatomy

Plasma Cells

Co-author Network

Publications

TOP 3
Teun Guichelaar; Henk M Lokhorst; Anton C Martens; Bianka Martini; Maarten E Emmelot; Richard W J Groen; Henk Rozemuller; Gert Storm; Tuna Mutis
Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells.
R Oostvogels; R M Spaapen; E Spierings; G D te Raa; Debbie Van Baarle; M van Elk; Arjan Buijs; B Giovannone; M Griffioen; Arnon P Kater; Henk M Lokhorst; Monique C Minnema; Tuna Mutis
Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
Annemiek Broyl; Arjan Buijs; Laila el Jarari; Hartmut Goldschmidt; Dirk Hose; Roland P Kuiper; Henk M Lokhorst; Pieter Sonneveld; Bronno van der Holt; Mark van Duin; Sonja Zweegman; Uta Bertsch
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Henk Lokhorst (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Teun Guichelaar; Henk M Lokhorst; Anton C Martens; Bianka Martini; Maarten E Emmelot; Richard W J Groen; Henk Rozemuller; Gert Storm; Tuna Mutis
Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(6):1467-75.
2013: R Oostvogels; R M Spaapen; E Spierings; G D te Raa; Debbie Van Baarle; M van Elk; Arjan Buijs; B Giovannone; M Griffioen; Arnon P Kater; Henk M Lokhorst; Monique C Minnema; Tuna Mutis
Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
Leukemia 2013;27(3):642-9.
2013: Annemiek Broyl; Arjan Buijs; Laila el Jarari; Hartmut Goldschmidt; Dirk Hose; Roland P Kuiper; Henk M Lokhorst; Pieter Sonneveld; Bronno van der Holt; Mark van Duin; Sonja Zweegman; Uta Bertsch
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
Blood 2013;121(4):624-7.
2012: Roland P Kuiper; Henk M Lokhorst; G Morgan; George Mulligan; A Broyl; Y de Knegt; L el Jarari; H Goldschmidt; W Gregory; E H van Beers; Bronno van der Holt; Mark van Duin; M H van Vliet; Pieter Sonneveld
A gene expression signature for high-risk multiple myeloma.
Leukemia 2012;26(11):2406-13.
2012: A C J Stork; W-Ludo van der Pol; D van Kessel; Henk M Lokhorst; Nicolette C Notermans
Effect of stem cell transplantation for B-cell malignancies on disease course of associated polyneuropathy.
Journal of neurology 2012;259(10):2100-4.
2012: Niels W C J van de Donk; Kenneth C Anderson; Henk M Lokhorst; Paul G Richardson
How I treat plasma cell leukemia.
Blood 2012;120(12):2376-89.
2012: Pieter Sonneveld; Marian Stevens-Kroef; Bronno van der Holt; Helgi van der Velde; Marinus van Marwijk Kooy; Edo Vellenga; Katja C Weisel; Pierre W Wijermans; Shulamiet Wittebol; Sonja Zweegman; Dirk Hose; Anna Jauch; Marie-Jose Kersten; Walter Lindemann; Henk M Lokhorst; Michael Pfreundschuh; Reinier Raymakers; Hans Salwender; M Ronald Schaafsma; Christof Scheid; Ingo G H Schmidt-Wolf; Uta Bertsch; Igor W Blau; Gerard M J Bos; Annemiek Broyl; Ulrich Duehrsen; Laila El Jarari; Hartmut M Goldschmidt
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(24):2946-55.
2012: Richard W J Groen; Frans M Hofhuis; Henk M Lokhorst; Linda Aalders; Andries C Bloem; Arjan Buijs; Joost D de Bruijn; Michel de Weers; Petra Moerer; Tuna Mutis; Willy A Noort; Paul W H I Parren; Henk-Jan Prins; Reinier A Raymakers; Henk Rozemuller; Jan Jacob Schuringa; Ellen van Binsbergen; Berris van Kessel; Jeroen F van Velzen; Huipin Yuan; Anton C M Martens
Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma.
Blood 2012;120(3):e9-e16.
2012: Henk M Lokhorst; Monique C Minnema; Reinier Raymakers; NP Schaap; Rianne Ammerlaan; Gerard Bos; Jan J Cornelissen; Okke de Weerdt; Jeroen J Janssen; Marie-José Kersten; Bronno van der Holt; Marinus van Oers; Shulamiet Wittebol; Mark Zijlmans; Sonja Zweegman; Pieter Sonneveld
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.
Blood 2012;119(26):6219-25; quiz 6399.
2012: N W C J van de Donk; Tuna Mutis; S Kamps; Henk M Lokhorst
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
Leukemia 2012;26(2):199-213.
2012: Kai Neben; Norma Peter; Michael Pfreundschuh; Marc S Raab; Hans Salwender; Christof Scheid; Ingo G H Schmidt-Wolf; Pieter Sonneveld; Christian Teschendorf; Helgi van de Velde; Bronno van der Holt; Katja Weisel; Mathias Haenel; Thomas Hielscher; Anthony D Ho; Dirk Hose; Anna Jauch; Walter Lindemann; Henk M Lokhorst; Hans Martin; Uta Bertsch; Igor W Blau; Hans G Derigs; Ulrich Dührsen; Hartmut Goldschmidt
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Blood 2012;119(4):940-8.
2012: Niels Wcj van de Donk; Güllü Görgün; Richard Wj Groen; Teru Hideshima; Jana Jakubikova; Jacob Laubach; Henk M Lokhorst; Constantine S Mitsiades; Inger S Nijhof; Reinier A Raymakers; Paul G Richardson; Kenneth C Anderson
Lenalidomide for the treatment of relapsed and refractory multiple myeloma.
Cancer management and research 2012;4():253-68.
2011: Silvia G R Verelst; Pierre W Wijermans; Shulamiet Wittebol; Sonja Zweegman; A H M Ammerlaan; Henk M Lokhorst; M Ronald Schaafsma; H A M Sinnige; Pieter Sonneveld; Fabian Termorshuizen; Carin A Uyl-de Groot; René van der Griend; Marinus van Marwijk Kooy
Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
Annals of hematology 2011;90(12):1427-39.
2011: S L Corthals; Y de Knegt; L el Jarari; M Jongen-Lavrencic; Roland P Kuiper; Henk M Lokhorst; Justine K Peeters; Berna Beverloo; A Broyl; Su Ming Sun; Bronno van der Holt; Sonja Zweegman; Pieter Sonneveld
MicroRNA signatures characterize multiple myeloma patients.
Leukemia 2011;25(11):1784-9.
2011: Evelien Kneppers; Henk M Lokhorst; Ellen Meijer; Tuna Mutis; Pieter Sonneveld; Bronno van der Holt; Sonja Zweegman; Cheryl P Bruijnen; Petra B Cornelisse; Jan J Cornelissen; Maarten Emmelot; Cynthia Huisman; Gerwin Huls; Jeroen J Janssen; Marie-Jose Kersten; Monique C Minnema
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Blood 2011;118(9):2413-9.
2011: Niels W C J van de Donk; Henk M Lokhorst; Meletios Dimopoulos; Michele Cavo; Gareth Morgan; Hermann Einsele; Martin Kropff; Steve Schey; Hervé Avet-Loiseau; Heinz Ludwig; Hartmut Goldschmidt; Pieter Sonneveld; Hans E Johnsen; Joan Bladé; Jesús F San Miguel; Antonio Palumbo
Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
Cancer treatment reviews 2011;37(4):266-83.
2011: David C Johnson; Sophie L Corthals; Brian A Walker; Fiona M Ross; Walter M Gregory; Nicholas J Dickens; Henk M Lokhorst; Hartmut Goldschmidt; Faith E Davies; Brian G M Durie; Brian Van Ness; J Anthony Child; Pieter Sonneveld; Gareth J Morgan
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(7):797-804.
2011: Michel de Weers; Yu-Tzu Tai; Michael S van der Veer; Joost M Bakker; Tom Vink; Daniëlle C H Jacobs; Lukas A Oomen; Matthias Peipp; Thomas Valerius; Jerry W Slootstra; Tuna Mutis; Wim K Bleeker; Kenneth C Anderson; Henk M Lokhorst; Jan G J van de Winkel; Paul W H I Parren
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(3):1840-8.
2011: Michael S van der Veer; Michel de Weers; Berris van Kessel; Joost M Bakker; Shulamiet Wittebol; Paul W H I Parren; Henk M Lokhorst; Tuna Mutis
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
Haematologica 2011;96(2):284-90.
2010: Robbert M Spaapen; Richard W J Groen; Kelly van den Oudenalder; Teun Guichelaar; Maureen van Elk; Tineke Aarts-Riemens; Andries C Bloem; Gert Storm; Anton C Martens; Henk M Lokhorst; Tuna Mutis
Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(22):5481-8.
2010: Annemiek Broyl; Sophie L Corthals; Joost Lm Jongen; Bronno van der Holt; Rowan Kuiper; Yvonne de Knegt; Mark van Duin; Laila el Jarari; Uta Bertsch; Henk M Lokhorst; Brian G Durie; Hartmut Goldschmidt; Pieter Sonneveld
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
The lancet oncology 2010;11(11):1057-65.
2010: Henk M Lokhorst; Hermann Einsele; David Vesole; Benedetto Bruno; Jesus San Miguel; Jose A Pérez-Simon; Nicolaus Kröger; Philippe Moreau; Gosta Gahrton; Cristina Gasparetto; Sergio Giralt; William Bensinger
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(29):4521-30.
2010: Annemiek Broyl; Dirk Hose; Henk M Lokhorst; Yvonne de Knegt; Justine Peeters; Anna Jauch; Uta Bertsch; Arjan Buijs; Marian Stevens-Kroef; Berna Beverloo; Edo Vellenga; Sonja Zweegman; Marie-Josée Kersten; Bronno van der Holt; Laila el Jarari; George Mulligan; Hartmut Goldschmidt; Mark van Duin; Pieter Sonneveld
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
Blood 2010;116(14):2543-53.
2010: Niels W C J van de Donk; Marijke R van Dijk; Henk M Lokhorst
Localized graft-versus-host disease of the skin provoked by radiotherapy.
Leukemia research 2010;34(10):e266-7.
2010: Pierre W Wijermans; Martijn Schaafsma; Fabian Termorshuizen; Rianne Ammerlaan; Shulamiet Wittebol; Harm Sinnige; Sonja Zweegman; Marinus van Marwijk Kooy; René van der Griend; Henk M Lokhorst; Pieter Sonneveld
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(19):3160-6.
2010: Sophie L Corthals; Mojca Jongen-Lavrencic; Yvonne de Knegt; Justine K Peeters; Berna Beverloo; Henk M Lokhorst; Pieter Sonneveld
Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma.
Leukemia research 2010;34(5):677-81.
2010: Evelien Kneppers; Henk M Lokhorst; Corien M Eeltink; Gerwin Huls; Marie José Kersten; Jan Koedam; Monique C Minnema; Marinus H J van Oers; Reinier A P Raymakers; Martijn R Schaafsma; Edo Vellenga; Pierre W Wijermans; Shulamiet Wittebol; Pieter Sonneveld; Sonja Zweegman
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Clinical lymphoma, myeloma & leukemia 2010;10(2):138-43.
2010: Henk M Lokhorst; Bronno van der Holt; Sonja Zweegman; Edo Vellenga; Sandra Croockewit; Marinus H J van Oers; Peter von dem Borne; Pierre W Wijermans; Ron Schaafsma; Okke de Weerdt; Shulamiet Wittebol; Michel Delforge; Henriëtte Berenschot; Gerard M Bos; Kon-Siong G Jie; Harm Sinnige; Marinus van Marwijk Kooy; Peter Joosten; Monique C Minnema; Rianne van Ammerlaan; Pieter Sonneveld
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
Blood 2010;115(6):1113-20.
2010: Monique C Minnema; Ellen van der Spek; Niels W C J van de Donk; Henk M Lokhorst
New developments in the treatment of patients with multiple myeloma.
The Netherlands journal of medicine 2010;68(1):24-32.
2010: Niels W C J van de Donk; Shulamit Wittebol; Monique C Minnema; Henk M Lokhorst
Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
British journal of haematology 2010;148(2):335-7.
2009: Robbert M Spaapen; Ron A L de Kort; Kelly van den Oudenalder; Maureen van Elk; Andries C Bloem; Henk M Lokhorst; Tuna Mutis
Rapid identification of clinical relevant minor histocompatibility antigens via genome-wide zygosity-genotype correlation analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(23):7137-43.
2009: Suzanne van Dorp; Floor Pietersma; Matthias Wölfl; Leo F Verdonck; Eefke J Petersen; Henk M Lokhorst; Edwin Martens; Matthias Theobald; Debbie Van Baarle; Ellen Meijer; Jürgen Kuball
Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(6):671-8.
2009: Ellen van der Spek; Andries C Bloem; Henk M Lokhorst; Berris van Kessel; Lijnie Bogers-Boer; Niels W C J van de Donk
Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
Leukemia research 2009;33(1):100-8.
2008: Robbert M Spaapen; Henk M Lokhorst; Kelly van den Oudenalder; Brith E Otterud; Harry Dolstra; Mark F Leppert; Monique C Minnema; Andries C Bloem; Tuna Mutis
Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis.
The Journal of experimental medicine 2008;205(12):2863-72.
2008: Coen Maas; José W P Govers-Riemslag; Barend Bouma; Bettina Schiks; Bouke P C Hazenberg; Henk M Lokhorst; Per Hammarström; Hugo ten Cate; Philip G de Groot; Bonno N Bouma; Martijn F B G Gebbink
Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.
The Journal of clinical investigation 2008;118(9):3208-18.
2008: Paul V Beum; Margaret A Lindorfer; Frank Beurskens; P Todd Stukenberg; Henk M Lokhorst; Andrew W Pawluczkowycz; Paul W H I Parren; Jan G J van de Winkel; Ronald P Taylor
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.
Journal of immunology (Baltimore, Md. : 1950) 2008;181(1):822-32.
2008: Henk Rozemuller; Ellen van der Spek; Lijnie H Bogers-Boer; Mieke C Zwart; Vivienne Verweij; Maarten Emmelot; Richard W Groen; Robbert Spaapen; Andries C Bloem; Henk M Lokhorst; Tuna Mutis; Anton Martens
A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
Haematologica 2008;93(7):1049-57.
2008: Ariënne M W van Marion; Johannes J A Auwerda; Ton Lisman; Pieter Sonneveld; Moniek P M de Maat; Henk M Lokhorst; Frank W G Leebeek
Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
Leukemia research 2008;32(7):1078-84.
2008: Monique C Minnema; Niels W C J van de Donk; Sonja Zweegman; Ute Hegenbart; S Schonland; Reinier A P Raymakers; J M J M Zijlmans; M J Kersten; G M J Bos; Henk M Lokhorst
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
Bone marrow transplantation 2008;41(9):779-84.
2008: Cynthia Huisman; Ellen Meijer; Eefke J Petersen; Henk M Lokhorst; Leo F Verdonck
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(2):181-6.
2008: Henk M Lokhorst; Bouke P C Hazenberg; Alexandra J Croockewit
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
The New England journal of medicine 2008;358(1):92; author reply 92-3.
2008: Henk M Lokhorst; Ingo Schmidt-Wolf; Pieter Sonneveld; Bronno van der Holt; Hans Martin; Renée M Y Barge; Uta Bertsch; Jana Schlenzka; Gerard M J Bos; Sandra Croockewit; Sonja Zweegman; Iris Breitkreutz; Iris Breitkreuz; Peter Joosten; Christof Scheid; Marinus van Marwijk Kooy; Hans Salwender; Marinus H J van Oers; Ron Schaafsma; Ralph Naumann; Harm Sinnige; Igor Blau; Michel Delforge; Gregor Verhoef; Okke de Weerdt; Pierre W Wijermans; Shulamiet Wittebol; Ulrich Duersen; Edo Vellenga; Hartmut Goldschmidt
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Haematologica 2008;93(1):124-7.
2007: Ellen van der Spek; Andries C Bloem; H A Sinnige; Henk M Lokhorst
High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.
Haematologica 2007;92(12):e130-1.
2007: Marijke Eurelings; Henk M Lokhorst; Nicolette C Notermans; Pieter-Jaap Krijtenburg; Berris van Kessel; Marc J Eleveld; Andries C Bloem; J H J Wokke; Martin Poot; Arjan Buijs
Cytogenetic aberrations in neuropathy associated with IgM monoclonal gammopathy.
Journal of the neurological sciences 2007;260(1-2):124-31.
2007: J M F Niermeijer; Marijke Eurelings; M W van der Linden; Henk M Lokhorst; Hessel Franssen; K Fischer; Laurien L Teunissen; Leonard H Van den Berg; F Schobben; J H J Wokke; Nicolette C Notermans
Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy.
Neurology 2007;69(1):50-9.
2007: Robbert Spaapen; Kelly van den Oudenalder; Roman Ivanov; Andries C Bloem; Henk M Lokhorst; Tuna Mutis
Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):4009-15.
2007: Pieter Sonneveld; Bronno van der Holt; Christine M Segeren; Edo Vellenga; Alexandra J Croockewit; Gregor E G Verhoe; Jan J Cornelissen; M Ronald Schaafsma; Marinus H J van Oers; Pierre W Wijermans; Petra H M Westveer; Henk M Lokhorst
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.
Haematologica 2007;92(7):928-35.
2007: Iris Breitkreutz; Henk M Lokhorst; Marc S Raab; B van der Holt; Friedrich W Cremer; Doris Herrmann; Axel Glasmacher; Ingo G H Schmidt-Wolf; I W Blau; H Martin; Hans Salwender; A Haenel; Pieter Sonneveld; Hartmut Goldschmidt
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield.
Leukemia 2007;21(6):1294-9.
2007: Barend Bouma; Coen Maas; Bouke P C Hazenberg; Henk M Lokhorst; Martijn F B G Gebbink
Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses.
Journal of thrombosis and haemostasis : JTH 2007;5(6):1139-42.
2007: S van Dorp; Ellen Meijer; Niels W C J van de Donk; Adriaan W Dekker; K Nieuwenhuis; Monique C Minnema; E Petersen; Roger Schutgens; Leo F Verdonck; Henk M Lokhorst
Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
The Netherlands journal of medicine 2007;65(5):178-84.
2007: Céline Schilthuizen; Annemiek Broyl; Bronno van der Holt; Yvonne de Knegt; Henk M Lokhorst; Pieter Sonneveld
Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.
Haematologica 2007;92(2):277-8.
2007: Ka Lung Wu; Berna Beverloo; Henk M Lokhorst; Christine M Segeren; Bronno van der Holt; Monique M C Steijaert; Petra H M Westveer; Pino J Poddighe; Gregor Verhoef; Pieter Sonneveld
Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
British journal of haematology 2007;136(4):615-23.
2006: J M F Niermeijer; Marijke Eurelings; Henk M Lokhorst; Hessel Franssen; R Fijnheer; J H J Wokke; Nicolette C Notermans
Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy.
Neurology 2006;67(11):2076-9.
2006: Niels W C J van de Donk; Nicolaus Kröger; Ute Hegenbart; Paolo Corradini; Jesús F San Miguel; Hartmut Goldschmidt; Jose A Perez-Simon; Maeike Zijlmans; Reinier A P Raymakers; Vittorio Montefusco; Francis Ayuk; Marinus H J van Oers; Arnon Nagler; Leo F Verdonck; Henk M Lokhorst
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
Bone marrow transplantation 2006;37(12):1135-41.
2006: Marijke Eurelings; Nicolette C Notermans; Henk M Lokhorst; Berris van Kessel; Bart C Jacobs; J H J Wokke; Surinder S Sahota; Andries C Bloem
Immunoglobulin gene analysis in polyneuropathy associated with IgM monoclonal gammopathy.
Journal of neuroimmunology 2006;175(1-2):152-9.
2006: S van Ruth; Henk M Lokhorst; C A F M Bruijnzeel-Koomen
[Two patients with hypereosinophilic syndrome].
Nederlands tijdschrift voor geneeskunde 2006;150(21):1193-7.
2006: Niels W C J van de Donk; Nicolaus Kröger; Ute Hegenbart; Paolo Corradini; Jesús F San Miguel; Hartmut Goldschmidt; Jose A Perez-Simon; Maeike Zijlmans; Reinier A P Raymakers; Vittorio Montefusco; Francis Ayuk; Marinus H J van Oers; Arnon Nagler; Leo F Verdonck; Henk M Lokhorst
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
Blood 2006;107(8):3415-6.
2006: Ellen van der Spek; Andries C Bloem; Niels W C J van de Donk; Lijnie H Bogers; René van der Griend; Mark H H Kramer; Okke de Weerdt; Shulamiet Wittebol; Henk M Lokhorst
Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma.
Haematologica 2006;91(4):542-5.
2006: Stefan O Schönland; Henk M Lokhorst; Agnès Buzyn; Veronique Leblond; Ute Hegenbart; Giuseppe Bandini; Andrew Campbell; Enric Carreras; Augustin Ferrant; Leanthe Grommisch; Peter Jacobs; Nicolaus Kröger; Giorgio La Nasa; Nigel Russell; Pierre Zachee; Hartmut Goldschmidt; Simona Iacobelli; Dietger Niederwieser; Gösta Gahrton
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.
Blood 2006;107(6):2578-84.
2006: Niels W C J van de Donk; Andries C Bloem; Ellen van der Spek; Henk M Lokhorst
New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway.
Current pharmaceutical design 2006;12(3):327-40.
2005: Ariënne M W van Marion; Johannes J A Auwerda; Monique C Minnema; Rolinda van Oosterom; Jelle Adelmeijer; Philip G de Groot; Frank W G Leebeek; Pieter Sonneveld; Henk M Lokhorst; Ton Lisman
Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis.
Thrombosis and haemostasis 2005;94(6):1341-3.
2005: Niels W C J van de Donk; Henk M Lokhorst; Andries C Bloem
Growth factors and antiapoptotic signaling pathways in multiple myeloma.
Leukemia 2005;19(12):2177-85.
2005: Ka Lung Wu; Wessel van Wieringen; Edo Vellenga; Sonja Zweegman; Henk M Lokhorst; Pieter Sonneveld
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Haematologica 2005;90(7):996-7.
2005: Marijke Eurelings; Henk M Lokhorst; Sandra Kalmijn; J H J Wokke; Nicolette C Notermans
Malignant transformation in polyneuropathy associated with monoclonal gammopathy.
Neurology 2005;64(12):2079-84.
2005: Ariënne M W van Marion; Henk M Lokhorst; Jan G van den Tweel
[Indications for bone marrow biopsy in adults].
Nederlands tijdschrift voor geneeskunde 2005;149(6):283-8.
2005: Niels W C J van de Donk; Henk M Lokhorst; Evert H J Nijhuis; Marloes M J Kamphuis; Andries C Bloem
Geranylgeranylated proteins are involved in the regulation of myeloma cell growth.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):429-39.
2005: Penny A Holloway; Niels Kaldenhoven; Henriette M Kok-Schoemaker; Mirjam van Dijk; Hennie G Otten; Marcel Tilanus; Saskia Postma; Tuna Mutis; Henk M Lokhorst; Andries C Bloem
A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution.
British journal of haematology 2005;128(1):73-81.
2004: Ellen Meijer; Adriaan W Dekker; Henk M Lokhorst; Eefke J Petersen; H Karel Nieuwenhuis; Leo F Verdonck
Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation.
Transplant infectious disease : an official journal of the Transplantation Society 2004;6(4):171-8.
2004: Monique C Minnema; Iris Breitkreutz; Johannes J A Auwerda; Bronno van der Holt; Friedrich W Cremer; Ariënne M W van Marion; Petra H M Westveer; Pieter Sonneveld; Hartmut Goldschmidt; Henk M Lokhorst
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
Leukemia 2004;18(12):2044-6.
2004: Hilke Bartels; Frederik G Dikkers; Jacqueline E van der Wal; Henk M Lokhorst; Bouke P C Hazenberg
Laryngeal amyloidosis: localized versus systemic disease and update on diagnosis and therapy.
The Annals of otology, rhinology, and laryngology 2004;113(9):741-8.
2004: Penny A Holloway; Niels Kaldenhoven; M van Dijk; Andries C Bloem; W de Lau; R van der Zee; B Kircher-Eibl; Tuna Mutis; Henk M Lokhorst
Susceptibility of malignant plasma cells to HA-1(H) specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect.
Leukemia 2004;18(9):1543-5.
2004: Niels W C J van de Donk; Okke de Weerdt; G Veth; Marijke Eurelings; E van Stralen; S R Frankel; Anton Hagenbeek; Andries C Bloem; Henk M Lokhorst
G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma.
Leukemia 2004;18(6):1078-84.
2004: Henk M Lokhorst; Kalung Wu; Leo F Verdonck; Laurens Laterveer; Niels W C J van de Donk; Marinus H J van Oers; Jan J Cornelissen; A V M B Schattenberg
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma.
Blood 2004;103(11):4362-4.
2004: Michel van Agthoven; Christine M Segeren; Ivonne Buijt; Carin A Uyl-de Groot; Bronno van der Holt; Henk M Lokhorst; Pieter Sonneveld
A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1159-69.
2004: Patrick W B Derksen; Esther P M Tjin; Helen P Meijer; Melanie D Klok; Harold D MacGillavry; Marinus H J van Oers; Henk M Lokhorst; Andries C Bloem; Hans Clevers; Roel Nusse; Ronald van der Neut; Marcel Spaargaren; Steven T Pals
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(16):6122-7.
2004: Ingrid I van Gameren; Henk M Lokhorst; Bouke P C Hazenberg; Edo Vellenga
Therapeutic options in systemic AL amyloidosis.
The Netherlands journal of medicine 2004;62(4):106-13.
2004: Yuk Yin Ng; Berris van Kessel; Henk M Lokhorst; Miranda Baert; Caroline M M van den Burg; Andries C Bloem; Frank Staal
Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity.
Journal of leukocyte biology 2004;75(2):314-23.
2003: Niels W C J van de Donk; Diana Schotte; Marloes M J Kamphuis; Ariënne M W van Marion; Berris van Kessel; Andries C Bloem; Henk M Lokhorst
Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5735-48.
2003: Niels W C J van de Donk; Marloes M J Kamphuis; Berris van Kessel; Henk M Lokhorst; Andries C Bloem
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.
Blood 2003;102(9):3354-62.
2003: Hartmut Goldschmidt; Pieter Sonneveld; Friedrich W Cremer; Bronno van der Holt; Petra H M Westveer; Iris Breitkreutz; Axel Benner; Axel Glasmacher; Ingo G H Schmidt-Wolf; H Martin; D Hoelzer; Anthony Ho; Henk M Lokhorst
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
Annals of hematology 2003;82(10):654-9.
2003: Paolo Corradini; Michele Cavo; Henk M Lokhorst; giovanni martinelli; Carolina Terragna; Ignazio Majolino; Pinuccia Valagussa; Mario Boccadoro; Diana Samson; Andrea Bacigalupo; Nigel Russell; Vittorio Montefusco; Claudia Voena; Gösta Gahrton
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.
Blood 2003;102(5):1927-9.
2003: Henk M Lokhorst; Christine M Segeren; Leo F Verdonck; Bronno van der Holt; Reinier A P Raymakers; Marinus H J van Oers; Renée M Y Barge; Harry C Schouten; Petra H M Westveer; Monique M C Steijaert; Jan J Cornelissen; Pieter Sonneveld
Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1728-33.
2003: Patrick W B Derksen; David de Gorter; Helen P Meijer; Richard Bende; M van Dijk; Henk M Lokhorst; Andries C Bloem; Marcel Spaargaren; Steven T Pals
The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.
Leukemia 2003;17(4):764-74.
2003: Christine M Segeren; Pieter Sonneveld; Bronno van der Holt; Edo Vellenga; Alexandra J Croockewit; Gregor Verhoef; Jan J Cornelissen; M Ronald Schaafsma; Marinus H J van Oers; Pierre W Wijermans; Wim E Fibbe; Shulamiet Wittebol; Harry C Schouten; Marinus van Marwijk Kooy; Douwe H Biesma; Joke W Baars; Rosalyn Slater; Monique M C Steijaert; Ivonne Buijt; Henk M Lokhorst
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
Blood 2003;101(6):2144-51.
2003: Monique C Minnema; Rob Fijnheer; Philip G de Groot; Henk M Lokhorst
Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment.
Journal of thrombosis and haemostasis : JTH 2003;1(3):445-9.
2003: Gienke R Boersma-Vreugdenhil; Ton Peeters; bert bast; Henk M Lokhorst
Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH.
Blood 2003;101(4):1653.
2003: Penny A Holloway; Niels Kaldenhoven; H M Kok-Schoemaker; Berris van Kessel; W T M Van Blokland; Andries C Bloem; Henk M Lokhorst
Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma.
Clinical and experimental immunology 2003;131(2):340-6.
2003: Laurens Laterveer; Leo F Verdonck; Ton Peeters; Erik Borst; Andries C Bloem; Henk M Lokhorst
Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma.
Blood 2003;101(3):1201-2.
2003: Niels W C J van de Donk; Marloes M J Kamphuis; M van Dijk; H P E Borst; Andries C Bloem; Henk M Lokhorst
Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
Leukemia 2003;17(1):211-9.
2002: K L Wu; M Ronald Schaafsma; Henk M Lokhorst; Pierre W Wijermans; Bronno van der Holt; Pieter Sonneveld
[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Nederlands tijdschrift voor geneeskunde 2002;146(31):1445-8.
2002: Niels W C J van de Donk; Marloes M J Kamphuis; Henk M Lokhorst; Andries C Bloem
The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells.
Leukemia 2002;16(7):1362-71.
2002: Yuk Yin Ng; Andries C Bloem; Berris van Kessel; Henk M Lokhorst; Ton Logtenberg; Frank Staal
Selective in vitro expansion and efficient retroviral transduction of human CD34+ CD38- haematopoietic stem cells.
British journal of haematology 2002;117(1):226-37.
2002: M van Driel; Ursula Günthert; A C van Kessel; P Joling; Reinhard Stauder; Henk M Lokhorst; Andries C Bloem
CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells.
Leukemia 2002;16(1):135-43.
2001: Pieter Sonneveld; Stefan Suciu; P Weijermans; M Beksac; R Neuwirtova; G Solbu; Henk M Lokhorst; Johannes Van Der Lelie; H Dohner; H Gerhartz; Christine M Segeren; Rein Willemze; B Lowenberg
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
British journal of haematology 2001;115(4):895-902.
2001: Wolfgang Eisterer; Oliver E Bechter; Wolfgang Hilbe; M van Driel; Henk M Lokhorst; Josef Thaler; Andries C Bloem; Ursula Günthert; Reinhard Stauder
CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma.
Leukemia research 2001;25(12):1051-7.
2001: Arjan Buijs; P Poddighe; Richard van Wijk; Wouter W van Solinge; E Borst; Leo F Verdonck; Anton Hagenbeek; P Pearson; Henk M Lokhorst
A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies.
Blood 2001;98(9):2856-8.
2001: Marijke Eurelings; Nicolette C Notermans; Niels W C J van de Donk; Henk M Lokhorst
Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy.
Muscle & nerve 2001;24(10):1295-302.
2001: Niels W C J van de Donk; Okke de Weerdt; Marijke Eurelings; Andries C Bloem; Henk M Lokhorst
Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors.
Leukemia & lymphoma 2001;42(4):609-18.
2001: Okke de Weerdt; Niels W C J van de Donk; G Veth; Andries C Bloem; Anton Hagenbeek; Henk M Lokhorst
Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma.
The Netherlands journal of medicine 2001;59(2):50-6.
2000: Henk M Lokhorst; A V M B Schattenberg; Jan J Cornelissen; Marinus H J van Oers; Willem E Fibbe; I Russell; N W Donk; Leo F Verdonck
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(16):3031-7.
2000: P Willems; O Verhagen; Christine M Segeren; P Veenhuizen; J Guikema; E Wiemer; L Groothuis; T B Jong; H Kok; Andries C Bloem; N Bos; Edo Vellenga; E J B M Mensink; Pieter Sonneveld; Henk M Lokhorst; E van Der Schoot; Reinier A P Raymakers
Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group.
Blood 2000;96(1):63-70.
2000: Yuk Yin Ng; P Veenhuizen; Henk M Lokhorst; Frank Staal
Frape-1 and Frape-3: two different recombinant retroviruses encoding the same human marker gene.
Cancer gene therapy 2000;7(4):624-8.
1999: Henk M Lokhorst; Pieter Sonneveld; Leo F Verdonck
Intensive treatment for multiple myeloma: where do we stand?
British journal of haematology 1999;106(1):18-27.
1999: D J Roovers; M van Vliet; Andries C Bloem; Henk M Lokhorst
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Leukemia research 1999;23(6):539-48.
1999: Christine M Segeren; Pieter Sonneveld; Bronno van der Holt; Joke W Baars; Douwe H Biesma; J J Cornellissen; Alexandra J Croockewit; Adriaan W Dekker; W E Fibbe; Bob Löwenberg; Marinus van Marwijk Kooy; Marinus H J van Oers; D J Richel; H C Schouten; Edo Vellenga; Gregor Verhoef; Pierre W Wijermans; Shulamiet Wittebol; Henk M Lokhorst
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
British journal of haematology 1999;105(1):127-30.
1999: J Kuipers; J W Vaandrager; D O Weghuis; Peter L Pearson; J M J C Scheres; Henk M Lokhorst; Hans Clevers; bert bast
Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.
Cancer genetics and cytogenetics 1999;109(2):99-107.
1999: Henk M Lokhorst; Pieter Sonneveld; Jan J Cornelissen; Peter Joosten; Marinus van Marwijk Kooy; J Meinema; H Karel Nieuwenhuis; Marinus H J van Oers; D J Richel; C N Segeren; G Veth; Leo F Verdonck; Pierre W Wijermans
Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
Bone marrow transplantation 1999;23(4):317-22.
1999: René van der Griend; Leo F Verdonck; Eefke J Petersen; P Veenhuizen; Andries C Bloem; Henk M Lokhorst
Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation.
Bone marrow transplantation 1999;23(2):195-7.
1999: Henk M Lokhorst; D Liebowitz
Adoptive T-cell therapy.
Seminars in hematology 1999;36(1 Suppl 3):26-9.
1998: Leo F Verdonck; Eefke J Petersen; Henk M Lokhorst; H Karel Nieuwenhuis; Adriaan W Dekker; Marcel G J Tilanus; Roel A de Weger
Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Bone marrow transplantation 1998;22(11):1057-63.
1998: HC van Zaanen; Henk M Lokhorst; Lucien A Aarden; H J Rensink; SO Warnaar; Marinus H J van Oers
Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Leukemia & lymphoma 1998;31(5-6):551-8.
1998: M van Driel; Ursula Günthert; Reinhard Stauder; P Joling; Henk M Lokhorst; Andries C Bloem
CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease.
Leukemia 1998;12(11):1821-8.
1998: HC van Zaanen; Henk M Lokhorst; Lucien A Aarden; H J Rensink; SO Warnaar; J van der Lelie; Marinus H J van Oers
Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.
British journal of haematology 1998;102(3):783-90.
1998: Henk M Lokhorst; Pieter Sonneveld; Pierre W Wijermans; Christine M Segeren
[Multiple myeloma; treatment in the year 1998].
Nederlands tijdschrift voor geneeskunde 1998;142(28):1596-602.
1998: Leo F Verdonck; Henk M Lokhorst; D J Roovers; HG van Heugten
Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.
Leukemia research 1998;22(3):249-56.
1998: W B de Lau; J Kuipers; Peter J Peters; Henk M Lokhorst; Hans Clevers; bert bast
Putative myeloma precursor cells expressing 2,6 sialic acid-modified antigens actually belong to the erythroid lineage.
Leukemia research 1998;22(2):163-73.
1998: Nicolette C Notermans; Henk M Lokhorst; R Wielaard; Douwe H Biesma; G J E Rinkel
[Clinical judgment and decision making in medical practice. A retiree with fatigue and foot drop].
Nederlands tijdschrift voor geneeskunde 1998;142(4):174-9.
1998: Andries C Bloem; T Lamme; M de Smet; H Kok; W Vooijs; J Wijdenes; S E Boom; Henk M Lokhorst
Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC-dependent cell lines.
British journal of haematology 1998;100(1):166-75.
1997: Henk M Lokhorst; A V M B Schattenberg; Jan J Cornelissen; L L Thomas; Leo F Verdonck
Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.
Blood 1997;90(10):4206-11.
1997: Leo F Verdonck; Adriaan W Dekker; Henk M Lokhorst; Eefke J Petersen; H Karel Nieuwenhuis
Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.
Blood 1997;90(10):4201-5.
1997: HC van Zaanen; Johannes A Romijn; Hans P Sauerwein; Henk M Lokhorst; SO Warnaar; Lucien A Aarden; Erik Endert; Marinus H J van Oers
Modulation of chronic excessive interleukin-6 production in multiple myeloma does not affect thyroid hormone concentrations.
Metabolism: clinical and experimental 1997;46(11):1343-8.
1997: Pieter Sonneveld; Henk M Lokhorst; P J M Vossebeld
Drug resistance in multiple myeloma.
Seminars in hematology 1997;34(4 Suppl 5):34-9.
1997: Nicolette C Notermans; M Vermeulen; Henk M Lokhorst; P A Van Doorn; Leonard H Van den Berg; Laurien L Teunissen; J H J Wokke
Pulsed high-dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy.
Journal of neurology 1997;244(7):462-3.
1997: Leonard H Van den Berg; Henk M Lokhorst; J H J Wokke
Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy.
Neurology 1997;48(4):1135.
1997: H van Ojik; Douwe H Biesma; Rob Fijnheer; Ronald J Hené; Henk M Lokhorst; S J Rooda; Leo F Verdonck
Cyclosporin for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation.
British journal of haematology 1997;96(3):641-3.
1996: Nicolette C Notermans; Henk M Lokhorst; Hessel Franssen; Y Van der Graaf; Laurien L Teunissen; F G Jennekens; Leonard H Van den Berg; J H J Wokke
Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.
Neurology 1996;47(5):1227-33.
1996: Reinhard Stauder; M Van Driel; Christoph Schwärzler; Josef Thaler; Henk M Lokhorst; Ernst D Kreuser; Andries C Bloem; Ursula Günthert; Wolfgang Eisterer
Different CD44 splicing patterns define prognostic subgroups in multiple myeloma.
Blood 1996;88(8):3101-8.
1996: H C van Zaanen; R P Koopmans; Lucien A Aarden; H J Rensink; J M Stouthard; S O Warnaar; Henk M Lokhorst; Marinus H J van Oers
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
The Journal of clinical investigation 1996;98(6):1441-8.
1996: Nicolette C Notermans; J H J Wokke; Leonard H Van den Berg; Y van der Graaf; Hessel Franssen; Laurien L Teunissen; Henk M Lokhorst
Chronic idiopathic axonal polyneuropathy. Comparison of patients with and without monoclonal gammopathy.
Brain : a journal of neurology 1996;119 ( Pt 2)():421-7.
1996: Leo F Verdonck; Henk M Lokhorst; Adriaan W Dekker; H Karel Nieuwenhuis; Eefke J Petersen
Graft-versus-myeloma effect in two cases.
Lancet 1996;347(9004):800-1.
1996: Henk M Lokhorst; Pieter Sonneveld; Pierre W Wijermans; Marinus van Marwijk Kooy; O J Meuwissen; R H van Oers; René van der Griend; Adriaan W Dekker
Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma.
British journal of haematology 1996;92(1):44-8.
1995: E J Ahsmann; M J van Tol; J Oudeman-Gruber; Henk M Lokhorst; F G Uytdehaag; H J Schuurman; Andries C Bloem
The SCID mouse as a model for multiple myeloma.
British journal of haematology 1995;89(2):319-27.
1994: Nicolette C Notermans; J H J Wokke; Henk M Lokhorst; Hessel Franssen; Y van der Graaf; F G Jennekens
Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities.
Brain : a journal of neurology 1994;117 ( Pt 6)():1385-93.
1994: Henk M Lokhorst; T Lamme; M de Smet; S Klein; Roel A de Weger; R van Oers; Andries C Bloem
Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures.
Blood 1994;84(7):2269-77.
1994: Leo F Verdonck; Adriaan W Dekker; Gijsbert C De Gast; M L van Kempen; Henk M Lokhorst; H Karel Nieuwenhuis
Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft.
Blood 1994;83(10):3090-6.
1994: J J Cornelissen; Pieter Sonneveld; M Schoester; H G Raaijmakers; H Karel Nieuwenhuis; Adriaan W Dekker; Henk M Lokhorst
MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):115-9.
1993: E J Ahsmann; Robert J Benschop; T D de Gruyl; J A Faber; Henk M Lokhorst; Andries C Bloem
A novel flow cytometric assay for the quantification of adhesion of subsets within a heterogeneous cell population; analysis of lymphocyte function-associated antigen-1 (LFA-1)-mediated binding of bone marrow-derived primary tumour cells of patients with multiple myeloma.
Clinical and experimental immunology 1993;93(3):456-63.
1993: Marinus H J van Oers; H C van Zaanen; Henk M Lokhorst
Interleukin-6, a new target for therapy in multiple myeloma?
Annals of hematology 1993;66(5):219-23.
1993: Henk M Lokhorst; Adriaan W Dekker
Advances in the treatment of multiple myeloma.
Cancer treatment reviews 1993;19(2):113-28.
1993: Pieter Sonneveld; B G Durie; Henk M Lokhorst; Y Frutiger; M Schoester; E E Vela
Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma.
British journal of haematology 1993;83(1):63-7.
1992: Leo F Verdonck; Adriaan W Dekker; Gijsbert C De Gast; M L van Kempen; Henk M Lokhorst; H Karel Nieuwenhuis
Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(12):1949-54.
1992: W E Terpstra; Henk M Lokhorst; F Blomjous; O J Meuwissen; Adriaan W Dekker
Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma.
British journal of haematology 1992;82(1):46-9.
1992: Pieter Sonneveld; B G Durie; Henk M Lokhorst; J P Marie; G Solbu; S Suciu; R Zittoun; B Löwenberg; K Nooter
Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.
Lancet 1992;340(8814):255-9.
1992: E J Ahsmann; Henk M Lokhorst; Adriaan W Dekker; Andries C Bloem
Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma.
Blood 1992;79(8):2068-75.
1992: Leo F Verdonck; Adriaan W Dekker; Gijsbert C De Gast; Henk M Lokhorst; H Karel Nieuwenhuis
Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(4):644-6.
1992: Henk M Lokhorst; O J Meuwissen; L F Verdonck; Adriaan W Dekker
High-risk multiple myeloma treated with high-dose melphalan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(1):47-51.
1989: Henk M Lokhorst; O J Meuwissen; bert bast; Adriaan W Dekker
VAD chemotherapy for refractory multiple myeloma.
British journal of haematology 1989;71(1):25-30.
1988: Henk M Lokhorst; S E Boom; W Terpstra; P Roholl; J Gerdes; bert bast
Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67.
British journal of haematology 1988;69(4):477-81.
1987: Henk M Lokhorst; S E Boom; bert bast; Peter J Peters; T F Tedder; J Gerdes; E Petersen; Rudy E Ballieux
Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern.
The Journal of clinical investigation 1987;79(5):1401-11.
1986: Henk M Lokhorst; S E Boom; bert bast; Rudy E Ballieux
Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique.
British journal of haematology 1986;64(2):271-5.